Analysis of DC-SIGN (CD209) Functional Variants in Patients with Tuberculosis

Luis M. Gómez, Juan Manuel Anaya, Elena Sierra-Filardi, Jose Cadena, Ángel Corbí, Javier Martín

Research output: Contribution to journalArticle

39 Scopus citations


Several lines of evidence suggest that host genetic factors controlling the immune response influence infection by Mycobacterium tuberculosis. Recently, DC-SIGN has been shown to be the major M. tuberculosis receptor on dendritic cells (DCs). The aim of this study was to investigate the influence of DC-SIGN functional polymorphisms -336G/A SNP in the promoter region and insertion/deletion in the "neck" region on the predisposition to tuberculosis. We performed an association study in 110 HIV-negative tuberculosis patients and 299 matched controls. In addition, a total of 155 healthy controls were screened for the tuberculin skin test (TST). DC-SIGN -336 SNP detection was performed by the real-time polymerase chain reaction technology, using the TaqMan 5′ allele. The insertion/deletion in the "neck" region was analyzed by polymerase chain reaction with specific primers. Although an increased frequency of the G allele in tuberculosis patients (23%), as compared with controls (19%), was observed, differences were not statistically significant (OR = 1.31, 95% CI = 0.89-1.94, P = 0.14). On the other hand, DC-SIGN repeat polymorphism in the "neck" region had a very low frequency in the analyzed population. We conclude that the studied polymorphisms are not relevant risk factors for developing tuberculosis in Northwestern Colombian individuals.

Original languageEnglish (US)
Pages (from-to)808-811
Number of pages4
JournalHuman Immunology
Issue number10
Publication statusPublished - Oct 1 2006



  • CD209
  • Colombia
  • tuberculin skin test
  • tuberculosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Gómez, L. M., Anaya, J. M., Sierra-Filardi, E., Cadena, J., Corbí, Á., & Martín, J. (2006). Analysis of DC-SIGN (CD209) Functional Variants in Patients with Tuberculosis. Human Immunology, 67(10), 808-811.